JP7630173B2 - ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物 - Google Patents

ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物 Download PDF

Info

Publication number
JP7630173B2
JP7630173B2 JP2021539453A JP2021539453A JP7630173B2 JP 7630173 B2 JP7630173 B2 JP 7630173B2 JP 2021539453 A JP2021539453 A JP 2021539453A JP 2021539453 A JP2021539453 A JP 2021539453A JP 7630173 B2 JP7630173 B2 JP 7630173B2
Authority
JP
Japan
Prior art keywords
nrg
day
mammal
myocardial infarction
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539453A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020143548A5 (https=
JP2022516199A (ja
JP2022516199A5 (https=
Inventor
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2022516199A publication Critical patent/JP2022516199A/ja
Publication of JPWO2020143548A5 publication Critical patent/JPWO2020143548A5/ja
Publication of JP2022516199A5 publication Critical patent/JP2022516199A5/ja
Priority to JP2024219524A priority Critical patent/JP7825894B2/ja
Application granted granted Critical
Publication of JP7630173B2 publication Critical patent/JP7630173B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021539453A 2019-01-07 2020-01-03 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物 Active JP7630173B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024219524A JP7825894B2 (ja) 2019-01-07 2024-12-16 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910015257.7 2019-01-07
CN201910015257 2019-01-07
CN201911412811.1 2019-12-31
CN201911412811.1A CN111407881A (zh) 2019-01-07 2019-12-31 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
PCT/CN2020/070299 WO2020143548A1 (zh) 2019-01-07 2020-01-03 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024219524A Division JP7825894B2 (ja) 2019-01-07 2024-12-16 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Publications (4)

Publication Number Publication Date
JP2022516199A JP2022516199A (ja) 2022-02-24
JPWO2020143548A5 JPWO2020143548A5 (https=) 2022-12-19
JP2022516199A5 JP2022516199A5 (https=) 2022-12-19
JP7630173B2 true JP7630173B2 (ja) 2025-02-17

Family

ID=71485079

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539453A Active JP7630173B2 (ja) 2019-01-07 2020-01-03 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
JP2024219524A Active JP7825894B2 (ja) 2019-01-07 2024-12-16 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024219524A Active JP7825894B2 (ja) 2019-01-07 2024-12-16 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Country Status (7)

Country Link
US (1) US20220096599A1 (https=)
EP (1) EP3909599A4 (https=)
JP (2) JP7630173B2 (https=)
CN (1) CN111407881A (https=)
AU (1) AU2020206381B2 (https=)
CA (1) CA3125377A1 (https=)
WO (1) WO2020143548A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118236430B (zh) * 2024-04-07 2025-08-26 中国人民解放军总医院第六医学中心 一种修复肿瘤治疗心肌损伤的药物组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503110A (ja) 2009-06-09 2013-01-31 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンに基づく心不全の治療方法
JP2016516016A (ja) 2013-03-06 2016-06-02 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
JP2018533922A (ja) 2015-09-25 2018-11-22 ダグラス ビー． ソーヤー， 心臓傷害を処置するための方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20010041869A1 (en) 2000-03-23 2001-11-15 Causey James D. Control tabs for infusion devices and methods of using the same
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7144384B2 (en) 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
US7128727B2 (en) 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
US20050065760A1 (en) 2003-09-23 2005-03-24 Robert Murtfeldt Method for advising patients concerning doses of insulin
US7686787B2 (en) 2005-05-06 2010-03-30 Medtronic Minimed, Inc. Infusion device and method with disposable portion
JP5738516B2 (ja) * 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
CN103768582A (zh) * 2006-12-29 2014-05-07 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
CN102245189B (zh) * 2008-12-03 2015-06-17 阿莫塞特公司 改善梗死区灌注的组合物以及血管损伤修复方法
JP6096262B2 (ja) * 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) * 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN103127579B (zh) 2011-11-21 2017-06-16 上海泽生科技开发股份有限公司 便携式注射泵的驱动系统
US10894815B2 (en) * 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
RU2015154737A (ru) * 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
WO2018052374A1 (en) * 2016-09-14 2018-03-22 Agency For Science, Technology And Research Modulation of tjp1 expression to regulate regeneration of heart cells
JP2017125032A (ja) * 2017-02-20 2017-07-20 ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド 糖尿病患者における心不全の治療用組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503110A (ja) 2009-06-09 2013-01-31 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンに基づく心不全の治療方法
JP2016516016A (ja) 2013-03-06 2016-06-02 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
JP2018533922A (ja) 2015-09-25 2018-11-22 ダグラス ビー． ソーヤー， 心臓傷害を処置するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zensen Announces Positive Clinical Results for NeucardinTM to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients，FIERCE Pharma，2013年，[Retrieved on 2023.11.30], Retrieved from the Internet: <URL: https://www.fiercepharma.com/pharma/zensun-announces-positive-clinical-results-for-neucardinTM-to-improve-heart-function-and>

Also Published As

Publication number Publication date
EP3909599A4 (en) 2022-09-28
EP3909599A1 (en) 2021-11-17
JP7825894B2 (ja) 2026-03-09
WO2020143548A1 (zh) 2020-07-16
CA3125377A1 (en) 2020-07-16
AU2020206381B2 (en) 2026-01-22
JP2025060703A (ja) 2025-04-10
AU2020206381A1 (en) 2021-07-29
CN111407881A (zh) 2020-07-14
US20220096599A1 (en) 2022-03-31
JP2022516199A (ja) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7209382B2 (ja) 心不全の治療用組成物
CN102232084B (zh) 纽兰格林及其用途
EP2528616B1 (en) Neuregulin based compositions and uses thereof for preventing or treating myocardial ischemia-reperfusion injury
EP3207940B1 (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
JP5956715B2 (ja) Ｅｔｂ受容体アゴニストを用いた脳卒中または脳血管障害の治療方法
KR102357275B1 (ko) 심부전을 치료하기 위한 뉴레귤린의 연장 방출
CN109276705B (zh) 治疗糖尿病患者心力衰竭的组份和方法
CN102159236A (zh) 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
JP7825894B2 (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
US20190000916A1 (en) Compositions and methods for modulating at2r activity
WO2020035012A1 (zh) 神经调节蛋白多肽片段及其用途
JP2017125032A (ja) 糖尿病患者における心不全の治療用組成物
JP2019112442A (ja) 糖尿病患者における心不全の治療用組成物および治療法
HK1241737A1 (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
HK1241737B (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
Hermans et al. Variable effects of UM206 on the wound healing after myocardial infarction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250128

R150 Certificate of patent or registration of utility model

Ref document number: 7630173

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150